Clinical trials: Nash
Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease
MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25-40%.Primary Hypothyroidism is one of Endocrinopathies who are at risk of developing NAFLD/NASH and estimated prevalence of Primary…
- Trial name
- SHIELD (NCT06373523)
- Testing
- Dapagliflozin 10mg Tab, Levothyroxine Replacement daily
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Conditionally Increased Output (CIO) Enhanced Ultrasound System
This study aims to assess possible bioeffects that may be caused by the use of shear wave elastography (SWE) with conditionally increased acoustic output pressure (CIO).
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05792423
- Testing
- GE ultrasound system with increased acoustic output settings
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Type 2 Diabetes Mellitus (T2DM), Non-Alcoholic Fatty Liver Disease (NAFLD)
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the…
- Trial name
- NCT06694935
- Testing
- QX1206
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- 1Globe Health Institute
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease…
- Trial name
- LFQ (NCT04657523)
- Testing
- Investigational Liver Fat Quantification Software
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Liver Steatoses
Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients
The aim of this study was to examine the association between metabolic associated fatty liver disease (MAFLD) in participants who had undergone cholecystectomy and those who had not undergone cholecystectomy.
- Trial name
- NCT06443723
- Testing
- USG, blood tests, waist, hip, height and blood pressure measurements
- Where
- Turkey (Türkiye)
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Metabolic Syndrome X, Fatty Liver
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by…
- Conditions
- Metabolic Syndrome X, Fatty Liver, MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD
- Trial name
- ACOUSTIQ (NCT06661655)
- Testing
- Liver ultrasound
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- E-Scopics
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum ranging from simple fatty liver over steatohepatitis (NASH) to liver cirrhosis and cancer (HCC) and is a major and increasing health problem affecting nearly 40% of…
- Trial name
- NCT02075164
- Testing
- Fructose, Glucose
- Where
- Austria
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Prof. Michael Trauner, MD
Non Alcoholic Fatty Liver, Osteo Arthritis
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease
This Study purpose to verify change of variety factors that the cause of nonalcoholic fatty liver disease and its process through salsalate injection to osteoarthritis patient who has non alcoholic fatty liver
- Trial name
- NCT03222206
- Testing
- Salsalate
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Korea University Guro Hospital
NAFLD
Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic disease ranging from fat accumulation in liver to fibrosis and cirrhosis. It affects 25% of the world population on average.
- Trial name
- NCT05521633
- Testing
- Metformin and Pioglitazone
- Where
- Pakistan
- Volunteers
- 96 people
- Sponsor
- King Edward Medical University
Bariatric Surgery Candidate, NAFLD
Effectiveness of Bariatric Surgery for NAFLD/NASH
This is a prospective, multicenter cohort study, which subjects were obese patients requiring bariatric surgery. This study aims to explore the the effectiveness of bariatric surgery for NAFLD/NASH with fribrosis, to explore the…
- Conditions
- Bariatric Surgery Candidate, NAFLD, NASH With Fibrosis
- Trial name
- NCT04366999
- Testing
- SG, RYGB, OAGB
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Beijing Friendship Hospital
NASH - Nonalcoholic Steatohepatitis
Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
This is a companion study assessing the ¹³C-Methacetin Breath Test (MBT) in subjects participating in the Bristol Myers-Squibb (BMS) NCT03486899 and NCT03486912 referenced studies using study drug BMS-986036.
- Trial name
- NCT03611101
- Testing
- ¹³C-Methacetin Breath Test, BMS-986036, BreathID MCS device
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Meridian Bioscience, Inc.
Fatty Liver, NAFLD
Impact of Exercise Intervention for Patients With Non-alcoholic Fatty Liver Disease
In Taiwan, with the westernization of eating habit and lifestyle, metabolic syndrome and non-alcoholic fatty liver (NAFLD) have become very important health issues.
- Trial name
- NAFLD (NCT04463667)
- Testing
- exercise
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Fatty Liver, Nonalcoholic, Liver Function
Enhanced Liver Function in Non-alcoholic Obese Fatty Liver Patients by Low Level Laser Therapy
Non-alcoholic fatty liver disease is excessive fat build-up in the liver with insulin resistance due to causes other than alcohol use.The obesity epidemic is closely associated with the rising prevalence and severity of…
- Trial name
- NCT04452409
- Testing
- low level laser, Mediterranean diet
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Non-alcoholic Fatty Liver Disease (NAFLD)
NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, underdiagnosed, health system burden and impacts on quality of life including comorbidities in the affected population.
- Trial name
- NASH-PI (NCT06688149)
- Testing
- Derivation algorithms
- Where
- 4 sites in Germany, Greece and 1 more
- Volunteers
- 536 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Hepatitis
Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
Nonalcoholic Steatohepatitis (NASH) is associated with progressive liver disease, fibrosis, and cirrhosis. Although the cause of NASH is unknown, it is often associated with obesity, type 2 diabetes, and insulin resistance.
- Trial name
- NCT00063232
- Testing
- Metformin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Fatty Liver Disease
Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objective is to test the hypothesis that 24 weeks of treatment with exenatide will improve the histological acitvity of NASH (steatosis,necroinflammation, ballooning), summarized in the recently introduced NASH-score…
- Trial name
- NCT01208649
- Testing
- Exenatide
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Ruhr University of Bochum
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.
- Trial name
- NCT04210245
- Testing
- aldafermin
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 160 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Non-Alcoholic Fatty Liver Disease
Liver Health and Metabolic Function in People With Obesity
This project aims to determine the effect of significant weight loss on rates on hepatic fibrogenesis in people with obesity.
- Trial name
- NCT03701828
- Testing
- Weight loss surgery
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Non-alcoholic Fatty Liver Disease
Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
This study design to examine performance of trigonella foenum-graecum (TFG) in treatment of non-alcoholic fatty liver disease. Base on inclusion and exclusion criteria, 50 patients select and then randomize into intervention and…
- Trial name
- NCT02303314
- Testing
- Trigonella Foenum-graecum Seed Extract
- Where
- Iran
- Volunteers
- 35 people
- Sponsor
- Shiraz University of Medical Sciences
Hepatitis
Treating Nonalcoholic Steatohepatitis With Pioglitazone
Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol.
- Trial name
- NCT00062764
- Testing
- Actos (Pioglitazone)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.